Drugs / ROSE12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05907980 | May 2023 → Dec 2026 expected | cancer | Chugai Pharmaceutical | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-28 | Chugai Pharmaceutical | Results Preclinical Results of the Anti-CTLA-4 Switch Antibody ROSE12 Published in the Journal for ImmunoTherapy of Cancer chugai-pharm.co.jp ↗
ROSE12 binds to CTLA-4 in the presence of ATP, exhibits antibody-dependent cellular cytotoxicity (ADCC) activity, and depletes Tregs. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-01-28 | Chugai Pharmaceutical | Preclinical Results of the Anti-CTLA-4 Switch Antibody ROSE12 Published in the Journal for ImmunoTherapy of Cancer chugai-pharm.co.jp ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROSE12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05907980 ↗ |
| Action | Deplete | “tumor-selective regulatory T-cell depletion” PMID 41513409 ↗ Jan 2026 |
| Route | Intravenous | “ROSE12 as a IV infusion” NCT05907980 ↗ |
| Target | CTLA4 | “ROSE12 demonstrated ATP concentration-dependent binding to CTLA-4” PMID 41513409 ↗ Jan 2026 |